On 1 October 2026, PHANCY (06682.HK) terminated its subscription agreement for new shares of Huanxi Media (01003.HK) as conditions precedent were unmet; the subscription will not proceed.
On 30 September 2026, CAMSENSE (06802.HK) received CSRC filing for an H-share issue and full circulation, to list up to 24,433,100 shares on HKEX.
On 30 September 2026, NEW WORLD DEV (00017.HK) said commitments under the VD Facility secured by Victoria Dockside rose to HK$4.9 billion.
On 30 September 2026, SFSY ENERGY (00750.HK) said the reconstruction of the 35MW Liupanshui project was completed under the new reconstruction plan.
On 30 September 2026, XINXIN MINING (03833.HK) said Xinjiang Mineral's shareholder changed to Xinjiang Non-Ferrous from the regional SASAC.
On 30 September 2026, FIRST CAP GP said it further extended the Consent Fee Deadline to 5:00 p.m. on 31 October 2026 for its proposed debt restructuring.
On 30 September 2026, SILVER GRANT said it received HKEX guidance on the trading suspension, with the 18-month period expiring on 24 March 2028.
On 30 September 2026, HAIWEI ELEC said it will refine its Southern China Facility to produce ultra-thin capacitor base films, with Phase I lines due in H2 2027.
On 30 September 2026, CSPC PHARMA reported positive Phase III results for its GLP-1 receptor agonist Efmedaglutide Alfa Injection in type 2 diabetes.
On 30 September 2026, HAIER SMARTHOME said it had repurchased 4,550,000 H shares for HK$93.58 million, or 0.049% of its total share capital, since 9 September.
On 30 September 2026, PERFECT MEDICAL (01830.HK) said INED Ji Zhixiong resigned and Qi Shichang was appointed remuneration committee chairman from that date.
On 30 September 2026, CHINA LONGYUAN (00916.HK) said it issued two 210-day ultra-short-term note tranches at a 1.35% coupon, raising RMB 3bn in total.
On 30 September 2026, MEIG (03268.HK) said its Shanghai joint venture Meige Guangxin has completed industrial and commercial registration with RMB 100m capital.
On 30 September 2026, HUSCOKE HLDGS (00704.HK) said Chen Kai has been appointed a non-executive director from that date, with no director's fee during his term.
On 30 September 2026, INSILICO (03696.HK) named ISM1354 a potentially best-in-class GIPR antagonist as preclinical candidate for obesity and type 2 diabetes.
On 29 Sept 2026, CIRC (01763.HK) sent a circular on a RMB3bn nuclear tech fund, committing RMB400m for 13.33% in a connected deal needing independent approval.
